James Greenan-Barrett

@jgreenanbarrett.bsky.social

NIHR Academic Clinical Fellow in Infectious Diseases | Specialist Registrar in Infectious Diseases & General Internal Medicine | UCL Respiratory & LSHTM | Interested in TB biomarkers, disease states & natural history

Optimising the use of currently available treatments through treatment stratification could reduce treatment duration by 2-months for the majority. TB treatment stratification strategies should be prospectively trialled in a phase III RCT. #TBSky

We’re hiring! Looking for a laboratory post-doc fellow to help us disentangle protective and pathogenic T cells in TB, so we can stratify disease-risk after infection, and develop more effective vaccines. Interdisciplinary science in the heart of London. What's not to like? More here: bit.ly/4iIEiwu

Bild

“…despite the recent introduction of BPaL/M, resistance to these new antituberculosis drugs has already developed in at least 27 countries across four continents. Furthermore, a quarter of these cases involved patient-to-patient transmission” Worrying stuff

Gabriele Pollara@gpollara.bsky.social · 2y ago

⚠️ Bit of an alarm bell to MDR-TB regimen BPaL/M - resistance to constituent antibiotics developing and transmission of such strains already occurring #TBSky #IDSky @nejm.org www.nejm.org/doi/10.1056/...

Historical evidence that mass CXR screening is feasible and effective Very cool study - lots to be learnt from the past… #TBSky

Peter MacPherson@petermacp.bsky.social · 2y ago

DYK in 1957, Glasgow, Scotland ran the largest ever screening campaign against #tuberculosis? 715,000 people (76% of entire adult population) were X-rayed over just 5 weeks! In a new study, we looked at the long-term impact of this campaign. journals.plos.org/plosmedicine... #episky #idsky 🧪🛟